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Background
Oropharyngeal HNSCCa is frequently associated with
HPV infection. DNA-based Immunotherapy with plas-
mids encoding HPV16 and HPV18 E6/E7 antigens has
been shown to generate robust immune responses in
women with HPV-driven high-grade cervical dysplasia.
We hypothesize that HPV-specific immunotherapy with
INO-3112 (VGX-3100 + INO-9012) in patients with
HPV-associated HNSCCa will generate robust immunity
which may contribute to disease stabilization or
regression.
Method
Eligibility for this prospective Phase I/IIa trial included
adults with HPV-positive (assessed by p16) HNSCCa,
ECOG PS 0-1, and adequate organ function. Patients
(pts) are enrolled into two cohorts. In Cohort 1, pts
receive INO-3112 pre and post-surgery. In Cohort 2, pts
receive INO-3112 after completion of cisplatin based
chemoradiation. INO-3112 (6mg of VGX-3100 plus 1mg
of INO-9012) is delivered IM followed by electroporation
with the CELLECTRA® device, once every 3 weeks for a
total of 4 doses. Pts are followed for 2 years. Primary and
secondary endpoints are safety and immune responses.
Exploratory endpoints include: anti-tumor effect and
progression-free-survival. Assessment of post-immunother-
apy surgical specimens is being done to evaluate vaccine-
induced lymphocyte infiltration in tumor.
Results
As of June 2015, 19 pts have been enrolled. Complete
safety data is available for 13 pts. Cohort 1: n=3, Cohort
2: n=10; 12 males; median age 57.7 years (range 39-76);
cancers at base of tongue=6, tonsil=6, soft palate=1;
never smoker=5, median follow-up is 104 days. INO-
3112 was well tolerated with no Grade 3 or higher AEs.
The most common AEs were injection site pain (n=11),
local erythema (n=4) and hematoma/swelling (n=2,
each). Two subjects had Grade 3 lymphopenia at base-
line and no worsening during the trial. There was a
Grade 2, unrelated SAE of post-surgical procedure
hemorrhage. Enrollment and correlative analysis are
ongoing; among samples tested to date, as compared to
baseline, 4 of 5 evaluable pts showed elevated anti
HPV16 and 18 E6/E7 antibody titers. Nine of 10 evalu-
able pts exhibited increased HPV-specific cellular
responses by IFN-gamma ELISpot. Seven of 8 evaluable
pts had HPV-specific CD8+ T cell activation concurrent
with increased lytic proteins (granzymes and perforin)
by flow cytometric analysis.1University of Pennsylvania, Philadelphia, PA, USA
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Conclusion
These interim results demonstrate that this DNA-based
immunotherapy (INO-3112) can safely generate HPV-
specific CD8 T cell immunity in patients with HPV-
related HNSSCa. All tested pts had positive cellular
immune responses in at least one assay.
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